Anti-CoV-RBD (G1) antibody

General information on Anti-CoV-RBD (G1) antibody

Neutralizing antibodies (NAbs) have been identified as key molecules for the treatment, prevention, and study of the COVID-19 disease. However, NAbs development against pathogenic agents can be a complex process due to the need to assess the neutralizing activity of many candidates in the early stages. Traditional methods of measuring viral neutralization comprise the use time-consuming virus neutralization test (VNT), pseudo-virus neutralization tests (pVNT), or the plaque reduction neutralization test (PRNT) which also require access to facilities with strict pathogen protection levels (biosafety level 3).
In the case of SARS-CoV-2, the etiological agent of the COVID-19 disease, NAbs are defined by their ability to block the interaction between the spike protein of the virus, particularly its receptor-binding domain (RBD), and the specific human cell surface receptor (ACE2).
The anti-CoV-RBD (G1) antibody belongs to a unique category of antibodies with potential neutralizing activity that have been isolated from a high diversity COVID-19 human antibody library (LiAb-SFCOVID-19™) using the recombinant form of RBD as the target antigen. Moreover, the neutralizing activity of the candidate was screening using our SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), which detects antibodies able to efficiently compete with ACE2 for the binding pocket of RBD. Additionally, the stability and ease of production of this antibody were validated by producing milligram amounts in the transient mammalian system XtenCHO™.
This antibody could serves as an efficient reagent to study COVID-19 disease progression and also as a potential surveillance tool to determine the development of long-term and short-term immunity to SARS-CoV-2 among the world’s population.